Genfit S.A. (EPA:GNFT)
9.10
-0.34 (-3.60%)
Oct 2, 2026, 5:35 PM CET
Genfit Revenue
Genfit had revenue of 25.03M EUR in the half year ending June 30, 2026, a decrease of -59.10%. This brings the company's revenue in the last twelve months to 60.48M, up 33.18% year-over-year. In the year 2025, Genfit had annual revenue of 71.12M with 0.25% growth.
Revenue (ttm)
60.48M
Revenue Growth
+33.18%
P/S Ratio
7.56
Revenue / Employee
373.96K
Employees
161
Market Cap
455.22M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 71.12M | 177.00K | 0.25% |
| Dec 31, 2024 | 70.94M | 32.76M | 85.83% |
| Dec 31, 2023 | 38.18M | 11.61M | 43.70% |
| Dec 31, 2022 | 26.57M | -59.01M | -68.96% |
| Dec 31, 2021 | 85.58M | 77.82M | 1,003.11% |
| Dec 31, 2020 | 7.76M | -33.20M | -81.06% |
| Dec 31, 2019 | 40.96M | 33.47M | 446.58% |
| Dec 31, 2018 | 7.49M | 639.00K | 9.32% |
| Dec 31, 2017 | 6.86M | 72.00K | 1.06% |
| Dec 31, 2016 | 6.78M | 2.43M | 55.64% |
| Dec 31, 2015 | 4.36M | -2.42M | -35.68% |
| Dec 31, 2014 | 6.78M | 808.40K | 13.55% |
| Dec 31, 2013 | 5.97M | -42.90K | -0.71% |
| Dec 31, 2012 | 6.01M | -768.20K | -11.33% |
| Dec 31, 2011 | 6.78M | 1.73M | 34.35% |
| Dec 31, 2010 | 5.05M | -5.79M | -53.43% |
| Dec 31, 2009 | 10.83M | -9.08M | -45.60% |
| Dec 31, 2008 | 19.91M | -296.57K | -1.47% |
| Dec 31, 2007 | 20.21M | 8.79M | 76.95% |
| Dec 31, 2006 | 11.42M | -1.77M | -13.43% |
| Dec 31, 2005 | 13.19M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 142.94M |
| Cellectis | 55.86M |
| MedinCell | 24.28M |
| Nanobiotix | 11.51M |
| Innate Pharma | 9.81M |
| Sensorion | 6.16M |
| Transgene | 5.62M |
| DBV Technologies | 4.41M |
Genfit News
- 4 days ago - Genfit Earnings release: Q2 2026 - Filings
- 4 days ago - Genfit Quarterly report: Q2 2026 - Filings
- 4 days ago - Earnings To Watch: Genfit SA (XPAR:GNFT) Q2 2026 -- GF Value Sees 27% Upside - GuruFocus
- 17 days ago - Genfit Slides: H.C. Wainwright 28th Annual Global Investment Conference presentation - Filings
- 17 days ago - GENFIT To Advance Nangibotide Into Phase 2 Trial For Acute-On-Chronic Liver Failure - Nasdaq
- 23 days ago - Genfit Transcript: KOL event - Transcripts
- 23 days ago - Genfit Press release: KOL event - Filings
- 23 days ago - Genfit Slides: KOL event - Filings